Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock: Insider Patricia Carr Sells 1,413 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,413 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total value of $326,911.68. Following the completion of the transaction, the chief accounting officer directly owned 6,512 shares in the company, valued at $1,506,616.32. The trade was a 17.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $234.76 on Friday. The stock has a market cap of $15.07 billion, a P/E ratio of 79.85, a PEG ratio of 0.44 and a beta of 0.38. The stock has a 50 day simple moving average of $229.39 and a 200 day simple moving average of $217.74. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals PLC has a 1-year low of $128.80 and a 1-year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm posted $8.13 EPS. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current year.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently modified their holdings of the stock. Aberdeen Group plc raised its stake in Jazz Pharmaceuticals by 16.5% in the third quarter. Aberdeen Group plc now owns 97,422 shares of the specialty pharmaceutical company’s stock valued at $22,555,000 after purchasing an additional 13,816 shares in the last quarter. JW Asset Management LLC acquired a new stake in Jazz Pharmaceuticals during the third quarter worth about $2,547,000. Russell Investments Group Ltd. grew its stake in Jazz Pharmaceuticals by 50.6% during the third quarter. Russell Investments Group Ltd. now owns 76,421 shares of the specialty pharmaceutical company’s stock worth $17,696,000 after buying an additional 25,671 shares in the last quarter. Eurizon Capital SGR S.p.A. increased its holdings in Jazz Pharmaceuticals by 46.1% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $757,000 after buying an additional 1,029 shares during the period. Finally, Maryland State Retirement & Pension System increased its holdings in Jazz Pharmaceuticals by 19.0% in the 3rd quarter. Maryland State Retirement & Pension System now owns 3,633 shares of the specialty pharmaceutical company’s stock valued at $841,000 after buying an additional 580 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Needham & Company LLC upped their price target on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Canaccord Genuity Group set a $300.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 26th. Wells Fargo & Company boosted their price objective on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. TD Cowen increased their target price on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Stifel Nicolaus set a $275.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $293.45.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.